SENSEX NIFTY
YOU ARE HERE >  Moneycontrol Markets > Announcements Pharmaceuticals
Ranbaxy Laboratories
BSE: 500359|NSE: RANBAXY|ISIN: INE015A01028|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Oct 01, 16:15
638.30
-1.4 (-0.22%)
VOLUME 90,255
LIVE
NSE
Oct 01, 16:15
638.40
-1.3 (-0.2%)
VOLUME 744,463
Announcements on Ranbaxy Labs

1st-Oct-2014 17:41Source: BSE

Ranbaxy Labs- Ranbaxy Launches ABSORICA® (isotretinoin) 25 mg and 35 mg Capsules in the U.S. Market

Ranbaxy Laboratories Ltd has informed BSE regarding a Press Release dated October 01, 2014 titled "Ranbaxy Launches ABSORICA® (isotretinoin) 25 mg and 35 mg Capsules in the U.S. Market".

29th-Sep-2014 13:49Source: BSE

Ranbaxy Labs- Q2 results on Oct 28, 2014

Ranbaxy Laboratories Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on October 28, 2014, inter alia, to consider and approve Standalone and Consolidated Unau...

24th-Sep-2014 13:52Source: NSE

Ranbaxy Laboratories Limited

Ranbaxy Laboratories Limited has submitted to the Exchange outcome of Court Convened Meeting of Equity Shareholders of the Company held on September 19, 2014.

24th-Sep-2014 13:48Source: BSE

Ranbaxy Labs- Outcome of Court Convened Meeting of Equity Shareholders

Ranbaxy Laboratories Ltd has informed BSE regarding "Court Convened Meeting of Equity Shareholders of the Company held on September 19, 2014".

17th-Sep-2014 17:44Source: NSE

Ranbaxy Laboratories Limited

Ranbaxy Laboratories Limited has informed the Exchange that the Company has received a Civil Investigative Demand ("CID") from the United States Department of Justice relating to the manner in which i...

17th-Sep-2014 17:04Source: BSE

Ranbaxy Labs- Receipt of Civil Investigative Demand ("CID") from the United States Department of Justice

Ranbaxy Laboratories Ltd has informed BSE that the Company has received a Civil Investigative Demand ("CID") from the United States Department of Justice relating to the manner in which it reports pri...

16th-Sep-2014 18:40Source: NSE

Ranbaxy Laboratories Limited

The Exchange had sought clarifiation from Ranbaxy Laboratories Limited with respect to a news item captioned "Pfizer, Ranbaxy win dismissal of lawsuit over generic Lipitor". The Company has clarified ...

2nd-Sep-2014 11:26Source: NSE

Ranbaxy Laboratories Limited

Ranbaxy Laboratories Limited has submitted to the Exchange vide letter dated September 2, 2014 a copy of disclosure pursuant to Regulation 13(4), 13(4A) and 13(6) of the SEBI (Prohibition of Insider T...

2nd-Sep-2014 11:06Source: BSE

Ranbaxy Labs- Disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992

Ranbaxy Laboratories Ltd has submitted the disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992

28th-Aug-2014 10:27Source: BSE

Ranbaxy Labs- Communication received from the Competition Commission of India in respect of the proposed combination between the Company and Sun Pharmaceutical Industries Ltd.

Ranbaxy Laboratories Ltd has informed BSE that the Company has received direction vide letter dated August 27, 2014 under Section 29(2) of the Competition Act, 2002 from the Competition Commission of ...

1 2 3 4 5 Next >>
Board Meeting (Ranbaxy Labs)

Meeting Date

Remark

2014-10-07

Special Dividend

2014-10-28

Quarterly Results

Quick Links for Ranbaxy Laboratories
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.